TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25552575
Drug: Intensive blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive blood pressure lowering (target SBP <140 mm Hg within 1 hour, lower limit of 130 mm Hg for treatment cessation)
Study: 21528598
Drug: Fluoxetine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (20 mg orally after breakfast)
Study: 20467616
Drug: 10‐ to
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10‐ to 16‐mm‐long implants after lateral sinus lifting with 50% anorganic bovine (Bio‐Oss) and 50% autogenous bone
Study: 20467616
Drug: 8‐mm‐long implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8‐mm‐long implants after crestal sinus lifting with autogenous bone
Study: 22872734
Drug: Adjuvanted recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvanted recombinant glycoprotein E vaccine (HZ/su; n = 45)
Study: 22872734
Drug: Live attenuated
Normalized name: mumps, live attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live attenuated Oka strain VZV vaccine (OKA; n = 45)
Study: 22872734
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of HZ/su and OKA administered concomitantly (n = 45)
Study: 22872734
Drug: Adjuvanted recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvanted recombinant glycoprotein E vaccine (HZ/su; n = 10) in young adults
Study: 22872734
Drug: Live attenuated
Normalized name: mumps, live attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live attenuated Oka strain VZV vaccine (OKA; n = 10) in young adults
Study: 16163369
Drug: Surfactant administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surfactant administration followed by extubation to NCPAP (N=52)
Study: 12745512
Drug: Nicotine inhaler
Normalized name: nicotine Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine inhaler (NI) plus nicotine patch (NP) (15 mg nicotine/16 h) for 6 weeks, then NI plus placebo patch (PP) for 6 weeks, then NI alone for 14 weeks.
Study: 12745512
Drug: Nicotine inhaler
Normalized name: nicotine Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine inhaler (NI) plus placebo patch (PP) for 12 weeks, then NI alone for 14 weeks.
Study: 8829892
Drug: Meloxicam 15
Normalized name: meloxicam 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meloxicam 15 mg suppositories
Study: 8829892
Drug: Piroxicam 20
Normalized name: piroxicam 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piroxicam 20 mg suppositories
Study: 2796625
Drug: EXACON thermal
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EXACON thermal therapy system model TT8200
Study: 81723
Drug: Intradermal skin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal skin tests
Study: 29271026
Drug: V-AC (vonoprazan
Approvals — FDA: no, EMA: no, PMDA: no
Description: V-AC (vonoprazan 20 mg bid, amoxicillin 750 mg bid, and clarithromycin 200 or 400 mg bid)
Study: 29271026
Drug: PPI-AC (lansoprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPI-AC (lansoprazole 30 mg, rabeprazole 10 mg, or esomeprazole 20 mg bid; amoxicillin 750 mg bid; and clarithromycin 200 or 400 mg bid)
Study: 27057659
Drug: Antidepressant medication
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant medication for comorbid depression
Study: 24129597
Drug: Palonosetron 0.075
Normalized name: palonosetron 0.075 MG in 1.5 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palonosetron 0.075 mg administered before induction of anaesthesia (pre-surgery group, n=50)
Study: 24129597
Drug: Palonosetron 0.075
Normalized name: palonosetron 0.075 MG in 1.5 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palonosetron 0.075 mg administered after surgery in the recovery room (post-surgery group, n=50)
Study: 23017153
Drug: Continuous outpatient
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous outpatient interdisciplinary rehabilitation programme (once weekly sessions)
Study: 20385971
Drug: Olmesartan medoxomil
Normalized name: Olmesartan Medoxomil
DrugBank: Olmesartan (DB00275)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olmesartan medoxomil (low-dose: 2.5 or 5 mg; high-dose: 20 or 40 mg)
Study: 20385971
Drug: Olmesartan medoxomil
Normalized name: Olmesartan Medoxomil
DrugBank: Olmesartan (DB00275)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olmesartan medoxomil (continued therapy)
Study: 18359175
Drug: 2mg oral
Normalized name: OPIPZA 2mg Oral Film
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2mg oral micronized estradiol (E2) (n=25)
Study: 18359175
Drug: 2mg oral
Normalized name: OPIPZA 2mg Oral Film
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2mg oral E2 + 1mg oral norethisterone acetate (NETA) (n=28)
Study: 16093400
Drug: Yam (Dioscorea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yam (Dioscorea alata) 390 g in 2 of 3 meals per day for 30 days
Study: 16093400
Drug: Sweet potato
Normalized name: Sweet Potato
DrugBank: Sweet potato (DB10648)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sweet potato 240 g for 41 days (control)
Study: 8672605
Drug: Ipsapirone (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipsapirone (0.5 mg/kg orally)
Study: 19622121
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (betamethasone dipropionate and calcipotriol)
Study: 12872081
Drug: Suck-and-ligate device
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suck-and-ligate device without prior submucosa injection
Study: 12872081
Drug: Cap technique
Normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cap technique with prior submucosa injection of dilute saline solution of epinephrine
Study: 1525801
Drug: Sodium valproate
Normalized name: sodium valproate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium valproate (500 mg, single oral dose)
Study: 3902675
Drug: KB-944 100
Normalized name: NF-KB Decoy
DrugBank: NF-kappaB Decoy (DB05559)
Approvals — FDA: no, EMA: no, PMDA: no
Description: KB-944 100 mg/day
Study: 3902675
Drug: KB-944 200
Normalized name: NF-KB Decoy
DrugBank: NF-kappaB Decoy (DB05559)
Approvals — FDA: no, EMA: no, PMDA: no
Description: KB-944 200 mg/day
Study: 30187284
Drug: Sodium selenite
Normalized name: Sodium selenite
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Sodium selenite (SS) 400 μg
Study: 30187284
Drug: Se-methylselenocysteine (MSC)
Normalized name: selenomethionine Se 75
DrugBank: Selenomethionine Se-75 (DB09400)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Se-methylselenocysteine (MSC) 400 μg
Study: 30187284
Drug: Seleno-l-methionine (SLM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seleno-l-methionine (SLM) 400 μg
Study: 28853492
Drug: Topical aprepitant
Normalized name: Aprepitant
DrugBank: Aprepitant (DB00673)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical aprepitant
Study: 22129066
Drug: Usual treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual treatment without NP diagnostics (control group, n=50)
Study: 17505919
Drug: HAART along
Normalized name: porcine heart preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: HAART along with syphilis and herpes simplex virus type 2 (HSV-2) treatment
Study: 11940726
Drug: Alendronate 10
Normalized name: ALENDRONATE 10MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate 10 mg/d fasting before breakfast
Study: 11940726
Drug: Alendronate 10
Normalized name: ALENDRONATE 10MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate 10 mg/d fasting at noon before lunch
Study: 1947851
Drug: ESWL treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: ESWL treatment by experienced surgeons (group A)
Study: 1947851
Drug: ESWL treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: ESWL treatment by inexperienced surgeons (group B)
Study: 31365044
Drug: Estradiol patch
Normalized name: Estradiol Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estradiol patch (200-μg)
Study: 15642722
Drug: Red wine
Normalized name: Red wine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red wine (150 ml, 15 g alcohol)
Study: 10979918
Drug: Albendazole (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albendazole (2 sequential doses of 400 mg)
Study: 9295004
Drug: Transdermal estradiol-17beta
Normalized name: Estradiol-17beta
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol-17beta (100 mg/day)
Study: 8333745
Drug: Postoperative chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative chemotherapy (CDDP 50 mg/m2 + VDS 3 mg/m2)
Study: 8333745
Drug: Postoperative chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative chemotherapy (CDDP + VDS)
Study: 2722305
Drug: Hypnotic induction
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hypnotic induction and suggestions derived from Rational‐Emotive Therapy, 4 weekly treatment sessions
Study: 28636208
Drug: PRN1008 (50-1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRN1008 (50-1200 mg single dose)
Study: 28636208
Drug: PRN1008 (300-900
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRN1008 (300-900 mg daily for 10 days)
Study: 28636208
Drug: PRN1008 (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRN1008 (single and multiple doses)
Study: 26142048
Drug: H pylori
Normalized name: Helicobacter pylori
Approvals — FDA: no, EMA: no, PMDA: no
Description: H pylori vaccine
Study: 24170762
Drug: Dietary fiber
Normalized name: Dietary Fiber 1.67 GM Oral Tablet, Chewable
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary fiber (quartiles from 8.7 to 21.8 g)
Study: 24170762
Drug: Vegetables and
Normalized name: Hydrogenated Vegetable Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vegetables and fruits (quartiles from 228.7 to 721.4 g)
Study: 24170762
Drug: Soluble dietary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soluble dietary fiber (per 1-g increase)
Study: 24170762
Drug: Total dietary
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total dietary fiber (per 1-g increase)
Study: 24170762
Drug: Insoluble dietary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insoluble dietary fiber (per 1-g increase)
Study: 18335698
Drug: EpiCor (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: EpiCor (500 mg daily)
Study: 16584855
Drug: Seretide Diskus
Normalized name: seractide
DrugBank: Seractide acetate (DB09334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Seretide Diskus (salmeterol xinafoate 50 mcg; fluticasone propionate 500 mcg)
Study: 16584855
Drug: Symbicort Turbuhaler
Normalized name: Symbicort Turbuhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symbicort Turbuhaler (formoterol 6 mcg; budesonide 200 mcg)
Study: 7684351
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin (subcutaneous injection, single fixed daily dose)
Study: 24522170
Drug: Once-daily insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily insulin detemir (initiated with mean 0.12 U/kg)
Study: 24522170
Drug: Twice-daily insulin
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily insulin detemir (initiated with mean 0.12 U/kg)
Study: 15976218
Drug: Remifentanil (Ce50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil (Ce50 5.0 ng/mL) during tracheal intubation (group TI, n = 20)
Study: 15976218
Drug: Remifentanil (Ce50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil (Ce50 2.1 ng/mL) during skin incision (group SI, n = 21)
Study: 12804052
Drug: Zevalin (ibritumomab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zevalin (ibritumomab tiuxetan) regimen including 5 mCi (111)In-labeled Zevalin on Day 1 and 0.4 mCi/kg (90)Y Zevalin on Day 8, preceded by 250 mg/m(2) rituximab.
Study: 8347333
Drug: Physostigmine 2
Normalized name: PHYSostigmine 2 mg/5 mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physostigmine 2 mg q2h while awake for 7 days plus yohimbine 10 mg and 20 mg challenges
Study: 8347333
Drug: Placebo q2h
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo q2h while awake for 5 days plus yohimbine 10 mg and 20 mg challenges
Study: 26501147
Drug: Aliskiren 150‐300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aliskiren 150‐300 mg/d
Study: 26501147
Drug: Hydrochlorothiazide (HCTZ)
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide (HCTZ) 12.5 ‐ 25 mg/d
Study: 15591711
Drug: Trofosfamide 90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trofosfamide 90 mg/m2
Study: 15591711
Drug: Trofosfamide 125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trofosfamide 125 mg/m2
Study: 15591711
Drug: Trofosfamide 175
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trofosfamide 175 mg/m2
Study: 15591711
Drug: Trofosfamide (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trofosfamide (all doses)
Study: 11494446
Drug: Manual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual therapy (MT) and point massage (PM)
Study: 11494446
Drug: Manual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual therapy (MT), point massage (PM), and bioresonance therapy (BRT)
Study: 3279083
Drug: Econazole cream
Normalized name: econazole Topical Cream
DrugBank: Econazole (DB01127)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Econazole cream 1%
Study: 29742708
Drug: Mokhuri treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mokhuri treatment program (Chuna, acupuncture, patient education)
Study: 29742708
Drug: Conventional nonsurgical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional nonsurgical treatments (drugs for pain relief, epidural steroid injections, physical therapy)
Study: 27465912
Drug: Elcatonin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elcatonin (20 units, weekly intramuscular injections)
Study: 27465912
Drug: NSAIDs (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: NSAIDs (oral nonsteroidal anti-inflammatory drugs)
Study: 24195205
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment (specific points: Sishenzhen, Zhisanzhen, Niesanzhen, Naosanzhan) for 4 months
Study: 24195205
Drug: Medication group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication group (piracetam tablets) for 4 months
Study: 21518561
Drug: Guideline for
Normalized name: LARYNGEAL GUIDEWIRE,PROVOX #7215
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guideline for the appropriate use of antibiotics in CABG during the perioperative period
Study: 16961161
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg ketoconazole once daily on Days 1 - 4 and 5 mg SPP301 on Day 3
Study: 16961161
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg SPP301 administered alone
Study: 15093636
Drug: Surodex dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Surodex dexamethasone anterior segment drug delivery system
Study: 9248770
Drug: Oral artemether
Normalized name: Artemether
DrugBank: Artemether (DB06697)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral artemether (300 mg)
Study: 9248770
Drug: Intramuscular artemether
Normalized name: Artemether
DrugBank: Artemether (DB06697)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular artemether (300 mg)
Study: 9248770
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of oral vs intramuscular artemether
Study: 2129004
Drug: Alternating therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternating therapy with MMC and BCG (Bacillus Calmette-Guérin)
Study: 361060
Drug: Diflucortolone valerate
Normalized name: diflucortolone valerate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diflucortolone valerate 0.3% ointment
Study: 15749316
Drug: Three-day course
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-day course of intravenous antibiotic prophylaxis with ampicillin and netilmicin (two daily doses for 72 h)
Study: 15749316
Drug: Single bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single bolus injection of intravenous antibiotic prophylaxis with ampicillin and netilmicin on admission
Study: 15749316
Drug: Three-day course
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-day course of intravenous antibiotic prophylaxis with ampicillin and netilmicin
Study: 12131109
Drug: Propofol infusion
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol infusion at a rate to achieve a target plasma concentration of 0.5 microg/ml
Study: 1858501
Drug: vitamin mineral
Normalized name: Multimineral/Multivitamin Oral Tablet [MULTI-VITAMIN MINERAL/BETA CAROTENE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: vitamin mineral pill with a high iron content
Study: 1858501
Drug: vitamin‐mineral pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: vitamin‐mineral pill
Study: 6353397
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg fenoterol via Hudson nebulizer
Study: 6353397
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg salbutamol via Hudson nebulizer
Study: 28625505
Drug: S-amlodipine nicotinate/olmesartan
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-amlodipine nicotinate/olmesartan medoxomil 5/40 mg (test product)
Study: 28625505
Drug: Amlodipine besylate/olmesartan
Normalized name: Amlodipine Besylate/Olmesartan Medoxomil 5 MG-20 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine besylate/olmesartan medoxomil 10/40 mg (reference product)
Study: 19816505
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with olmesartan medoxomil (OLM) 20 mg plus azelnidipine (AZL) 16 mg (O/A (20/16))
Study: 19816505
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with olmesartan medoxomil (OLM) 10 mg plus azelnidipine (AZL) 8 mg (O/A (10/8))
Study: 19816505
Drug: Monotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy with olmesartan medoxomil (OLM) 20 mg (OLM (20))
Study: 19816505
Drug: Monotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy with azelnidipine (AZL) 16 mg (AZL (16))
Study: 15630900
Drug: Heterozygous AAT
Normalized name: ARO-AAT
DrugBank: Fazirsiran (DB17891)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heterozygous AAT variants (MZ, MS, MF, ML, ME)
Study: 11378833
Drug: MPA 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: MPA 2.5 mg
Study: 11378833
Drug: MPA 5
Normalized name: MPA
DrugBank: Medroxyprogesterone acetate (DB00603)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MPA 5 mg
Study: 11378833
Drug: MPA 10
Normalized name: Fycompa 10mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: MPA 10 mg
Study: 11378833
Drug: MPA 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: MPA 2.5 mg, MPA 5 mg, MPA 10 mg
Study: 3989036
Drug: 30 ml
Normalized name: Vial M/T 30 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 ml Gastrografin
Study: 3989036
Drug: 20 ml
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml Gastrografin
Study: 3989036
Drug: dilute barium
Normalized name: barium
DrugBank: Barium (DB12481)
Approvals — FDA: no, EMA: no, PMDA: no
Description: dilute barium (600 ml)
Study: 30868829
Drug: Qingying Tang,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qingying Tang, 150 mL/time, twice a day for 12 weeks
Study: 30868829
Drug: Acitretin Capsules,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acitretin Capsules, 10 mg/time, twice a day for 12 weeks
Study: 24676931
Drug: Vorapaxar 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vorapaxar 2.5 mg daily
Study: 20462978
Drug: TS-1 (40-60
Approvals — FDA: no, EMA: no, PMDA: no
Description: TS-1 (40-60 mg twice daily for 28 consecutive days, followed by a 14-day rest period)
Study: 20462978
Drug: Taxanes (docetaxel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taxanes (docetaxel 60-75 mg/m(2) at 3- or 4-week intervals, paclitaxel 175 mg/m(2) at 3- or 4-week intervals or paclitaxel 80-100 mg/m(2) weekly, followed by a 1-week rest period)
Study: 16194646
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg of elemental iron (liquid ferrous gluconate) for 60 days
Study: 16194646
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg of ferrous calcium citrate tablets for 60 days
Study: 16194646
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg of iron for 60 days (control group)
Study: 26639678
Drug: Sublingual buprenorphine/naloxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual buprenorphine/naloxone (BNX)
Study: 26639678
Drug: Oral naltrexone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral naltrexone (NTX)
Study: 18647128
Drug: CBGT+EX (exercise-enhanced
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBGT+EX (exercise-enhanced cognitive behavioural group therapy)
Study: 18647128
Drug: CBGT+ED (usual
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBGT+ED (usual cognitive behavioural group therapy plus nutrition education)
Study: 16948354
Drug: Montelukast, 5-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast, 5-mg tablets for 1 month
Study: 16948354
Drug: Montelukast, before
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast, before treatment
Study: 8824057
Drug: Amitriptyline (AMI),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline (AMI), 5 mg/kg per day
Study: 31092695
Drug: ACCi-1 (acetyl-CoA
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACCi-1 (acetyl-CoA carboxylase inhibitor), dosed orally for 2 weeks
Study: 31092695
Drug: ACCi-1 (acetyl-CoA
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACCi-1 (acetyl-CoA carboxylase inhibitor)
Study: 25230962
Drug: Intracameral dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intracameral dexamethasone (0.4 mg/0.1 ml)